Mr. Nice Seeds was established by Howard Marks and Scott Blakey (Shantibaba) in the early 2000s, named after Howard Marks’s autobiography. Shantibaba had previously been a founding breeder at Green House Seeds, where he co-developed White Widow. Mr. Nice Seeds’ catalogue is deliberately small and focused on quality and stability over catalogue size, with every strain representing a considered breeding programme. Shark Shock is among their most medically significant offerings.
White Widow, the first parent, was one of the breakthrough strains of 1990s Amsterdam coffeeshop culture: a Brazilian sativa x South Indian indica hybrid known for intense resin production and a balanced effect profile. It won the Cannabis Cup in 1995 and established the template for high-resin hybrid strains that defined European cannabis breeding for the following decade. Skunk #1, the second parent, is one of the most foundational strains in Western cannabis genetics — a stable, vigorous hybrid of Afghani, Acapulco Gold, and Colombian Gold, developed by Sam the Skunkman in the 1970s and introduced to Europe in the 1980s.
The CBD content in Shark Shock at 4–6% reflects a breeding characteristic that was present in early Skunk genetics (Skunk #1 carries residual CBD from its Afghani heritage) and was reinforced by selection. Before the commercialisation of CBD-specific strains post-2015, Shark Shock was one of a very small number of hybrid strains available with meaningful CBD content, making it a sought-after medical cannabis option for patients who found pure THC strains too anxiety-producing or intoxicating for their medical needs.
| Strain | Genetics | Key Contribution to Shark Shock | Historical Significance |
|---|---|---|---|
| White Widow | Brazilian Sativa × South Indian Indica | Resin production, pine-sweet aroma, balanced THC | Cannabis Cup 1995, Amsterdam icon |
| Skunk #1 | Afghani × Acapulco Gold × Colombian Gold | CBD content, earthy vigour, yield, stability | Foundational Western hybrid; Sam the Skunkman |
| Shark Shock | White Widow × Skunk #1 | THC 14–19% / CBD 4–6%, earthy-sweet-pine, CBD-rich medical indica | Mr. Nice Seeds; early CBD-rich commercial strain |
The pharmacological significance of Shark Shock’s THC:CBD ratio cannot be overstated for medical cannabis users. CBD modulates THC’s effects through multiple mechanisms: it acts as a partial antagonist at CB1 receptors (reducing THC intoxication intensity), inhibits the cytochrome P450 enzymes that metabolise THC (extending duration), and activates its own receptor pathways (5-HT1A serotonin receptors, TRPV1 pain receptors, and GPR55 orphan receptors) that have independent therapeutic value.
The practical result: Shark Shock at 15% THC / 5% CBD feels and functions differently from a 15% THC-only strain. The intoxication is gentler and less anxiety-producing. The anti-inflammatory and analgesic effect duration is extended. The anticonvulsant activity (CBD’s most well-documented medical property) is present. And the overall therapeutic window is wider — allowing medical dosing throughout the day in some patients who cannot tolerate pure THC strains functionally.
| Compound | Typical Range | Effect / Therapeutic Role | Aroma Note |
|---|---|---|---|
| THC | 14–19% | Analgesia, body relaxation, mood lift, appetite | — |
| CBD | 4–6% | Anti-inflammatory, anticonvulsant, anti-anxiety, CB1 modulation, 5-HT1A | — |
| Myrcene | Moderate–High | Sedation, muscle relaxation; amplifies CBD synergistically | Earthy, herbal |
| Caryophyllene | Moderate (>0.4%) | CB2 anti-inflammatory (complements CBD anti-inflammatory pathway) | Spice, skunk note, pepper |
| Pinene (α) | Moderate (from White Widow) | Bronchodilation, cognitive clarity, acetylcholinesterase inhibition | Pine, fresh |
| Ocimene | Low | Uplifting, sweet | Sweet, herbal |
Shark Shock’s effect profile is distinctly different from pure THC indica strains and the difference is entirely attributable to the CBD content. The onset is gradual (15–25 minutes), consistent with both the indica character and the CBD moderating influence on THC onset speed. The initial experience is a comfortable warmth and mild mood elevation — noticeably gentler and less intoxicating than a comparable THC-only strain at similar THC percentage.
Body relaxation builds progressively over 30–60 minutes, with the CBD amplifying the myrcene muscle-relaxation pathway and adding its own TRPV1 pain receptor activity. The result is a full-body ease that many medical users describe as “therapeutic relaxation” rather than “intoxicated sedation” — an important distinction for patients who need to remain functional during the day. Anxiety is significantly reduced compared to THC-only strains of comparable potency, and the paranoia risk that some users experience with high-THC cannabis is substantially mitigated by the CBD co-administration.
At standard doses, Shark Shock produces a functional, mildly sedating indica effect suitable for late afternoon or evening use in most medical and recreational users. At higher doses, the full body relaxation transitions toward sleep-readiness. The effects are durable — typically 2–4 hours — and the comedown is gradual and comfortable, consistent with CBD’s ability to extend THC metabolisation.
| Parameter | Pure THC Indica (15-19%) | Shark Shock (THC + CBD) |
|---|---|---|
| Intoxication intensity | High | Moderate (CBD modulated) |
| Anxiety risk | Moderate–High | Low (CBD buffer) |
| Anti-inflammatory duration | Moderate | Extended (CBD + Caryophyllene CB2) |
| Anticonvulsant activity | Minimal | Significant (CBD) |
| Functional daytime use | Difficult at full dose | Possible at low–moderate dose |
| Effect duration | 2–3 hours | 2–4 hours (CBD extends) |
Shark Shock’s aroma is a well-balanced expression of both parent strains. The White Widow heritage contributes a sweet, pine-fresh, almost floral note with the characteristic crystal-white trichome visual counterpart. The Skunk #1 heritage adds the earthy, slightly funky-sweet depth that is more muted than full Skunk #1 but unmistakably present. The combination creates an earthy-sweet-pine profile that is pleasant, accessible, and without the polarising extremes of fuel/diesel or pure skunk notes that some users find off-putting.
On the exhale, the sweet-earth-pine combination has a mellow, herbal finish characteristic of CBD-rich cannabis — there is a faint green-herbal note in high-CBD strains that experienced users associate with the CBD terpene-cannabinoid interaction. The aroma is not as striking or memorable as the highest-impact strains in the cannabis world, but it is consistently pleasant, consistently recognisable as premium indica, and extremely appropriate for medical consumption contexts.
Shark Shock’s medical profile is among the broadest of any strain on this guide. The 4–6% CBD opens medical applications that are inaccessible to pure THC strains: conditions requiring anticonvulsant activity (epilepsy spectrum disorders, febrile seizures), conditions requiring strong anti-inflammatory effect (inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), and conditions where THC anxiety is a clinical barrier to use (anxiety disorders, PTSD with hyperreactivity to intoxicants, patients who have discontinued high-THC cannabis due to adverse psychological reactions).
Pain management for inflammatory pain conditions (arthritis, fibromyalgia, neuropathy) receives a dual pathway treatment from Shark Shock: the THC CB1 analgesic pathway plus the CBD TRPV1 pain pathway plus the caryophyllene CB2 anti-inflammatory pathway. This represents a more comprehensive pharmacological pain treatment than any single-mechanism approach. For MS patients, the CBD anticonvulsant and muscle-relaxation pathway combined with THC body relaxation provides genuine spasticity relief. For cancer patients or those undergoing chemotherapy, Shark Shock’s antiemetic properties (shared between THC and CBD) plus mild appetite stimulation address nausea and appetite loss without overwhelming intoxication.
| Condition | Primary Mechanisms | Evidence Level | Dose / Timing |
|---|---|---|---|
| Epilepsy / seizure disorders | CBD anticonvulsant (GPR55, sodium channel) | Clinical evidence (Epidiolex) | Under medical supervision only |
| Inflammatory pain (arthritis, fibro) | THC CB1 + CBD TRPV1 + Caryophyllene CB2 | High patient-reported | Moderate, daytime to evening |
| Multiple sclerosis spasticity | CBD anticonvulsant + THC/Myrcene muscle relaxation | Clinical (Sativex reference) | Low–moderate, throughout day |
| Anxiety + THC intolerance | CBD 5-HT1A + CB1 partial antagonism | High patient-reported | Low dose, afternoon–evening |
| Nausea / chemotherapy support | THC + CBD antiemetic pathways | Well-established | Low–moderate as needed |
| Insomnia (moderate) | Myrcene + THC + CBD calming | Moderate patient-reported | Moderate, pre-sleep |
Shark Shock inherits the best cultivation qualities of both parent strains. White Widow’s genetics contribute exceptional mould and pest resistance alongside the heavy resin production that makes the strain visually distinctive. Skunk #1’s genetics contribute vigour, yield consistency, and a robust, forgiving growth pattern that is appropriate for intermediate growers. The result is a reliable, rewarding grow that over-delivers in both quality and the unique satisfaction of producing a genuinely CBD-rich strain at home.
The 8–9 week flower time is compact for the quality level. Plants grow to moderate height (80–110cm indoor) with the bushy, multi-branching structure characteristic of indica-dominant genetics. By week 6 of flower, the trichome development becomes dramatic — the White Widow heritage means Shark Shock develops a visible white frost that blankets the buds and even sugar leaves, explaining the visual character of the White Widow parent. This resin density makes Shark Shock an excellent source for CBD-rich rosin and bubble hash production.
CBD content in the final product is strongly influenced by genetics — CBD content is genetically determined rather than environmentally manipulated — so selecting verified Shark Shock genetics from a reputable source is essential for growers targeting the 4–6% CBD range. Lab verification of CBD content is strongly recommended for medical growers who need to accurately dose CBD alongside THC.
| Parameter | Indoor | Outdoor | Notes |
|---|---|---|---|
| Flower Time | 8–9 weeks | Late September–early October | Reliable timing |
| Yield Indoor | 400–500g/m² | 500–700g/plant | Solid for indica medical cultivar |
| Height | 80–110cm | 100–150cm | Compact indica structure |
| Difficulty | Easy–Moderate | Easy | Recommended for home medical growers |
| Mould Resistance | High (White Widow heritage) | High | Significantly more resistant than most hybrids |
| Resin / CBD Production | Exceptional (visually white by week 7) | Exceptional | CBD content is genetic, not environmental |
| Lab Verification | Strongly recommended | Strongly recommended | Medical growers should verify CBD:THC ratio by batch |
Medical users consuming Shark Shock for its CBD benefits should be aware that the CBD content changes the pharmacokinetics compared to pure THC strains. The CBD extends the effective duration by inhibiting THC metabolism, meaning doses remain active for longer — typically 2–4 hours versus 2–3 hours for comparable pure THC strains. The reduced intoxication intensity from CBD modulation allows some medical patients to use Shark Shock during afternoon or early evening hours when pure THC indicas would be too impairing.
Vaporisation at 160–180°C is optimal for the terpene-CBD interaction: lower temperatures preserve the delicate sweet-pine terpenes while still releasing both THC and CBD effectively. CBD has a slightly higher boiling point than THC but both are efficiently volatilised in this range. For patients requiring the highest CBD dose, water-pipe or vaporiser hits at the lower end of the temperature range maximise CBD relative to THC through the slight differential volatilisation effect.
Shark Shock is an indica-dominant cannabis strain created by Mr. Nice Seeds (Howard Marks and master breeder Shantibaba) by crossing White Widow with Skunk #1. It contains THC 14–19% and CBD 4–6%, making it one of the most CBD-significant hybrid strains available. It was one of the first commercially available high-CBD hybrid strains and predates the widespread CBD strain movement by years. Earthy-sweet-pine aroma, relaxing mild effects.
Shark Shock is particularly valuable for: inflammatory pain conditions (arthritis, fibromyalgia, neuropathy) where the dual THC/CBD anti-inflammatory pathway outperforms THC alone; multiple sclerosis spasticity (CBD anticonvulsant + muscle relaxation); epilepsy spectrum disorders (CBD anticonvulsant — under medical supervision only); anxiety complicated by THC intolerance (CBD moderates THC anxiety); nausea from chemotherapy; and moderate insomnia. Its CBD content provides therapeutic benefits inaccessible with pure THC strains.
CBD at 4–6% meaningfully changes the experience in four ways: (1) reduced intoxication intensity — CBD partially blocks CB1 receptors, making the THC effect gentler; (2) lower anxiety and paranoia risk — CBD’s 5-HT1A activation and CB1 modulation reduce THC-induced anxiety; (3) extended effect duration — CBD inhibits THC metabolism, lasting 2–4 hours vs. 2–3; (4) additional anti-inflammatory and anticonvulsant pathways not present in THC-only strains.
No. Shark Shock (White Widow × Skunk #1 by Mr. Nice Seeds) and Shark’s Breath (typically a Great White Shark × OG Kush cross by DNA Genetics) are different strains from different breeders with different genetics and different cannabinoid profiles. Both have “shark” in the name but share no direct genetic connection. Shark Shock is specifically notable for its CBD content; Shark’s Breath is a higher-THC OG-influenced hybrid.